Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
With proper treatment, individuals with atrial fibrillation can live normal and active lives.
Many people experience a slight quivering or racing heart at some point and usually give it little notice. But for those diagnosed with atrial fibrillation, that irregular heartbeat can be a serious condition that can increase the risk of stroke and needs medical attention.
Two new guidelines have many clinicians, newscasters, and patients talking.
Used to treat deep vein thrombosis and pulmonary embolism, apixaban provides considerable added benefit to overweight patients.
Latest Issues
$auto_registration$